Bavarian Nordic’s VIMKUNYA™ A Chikungunya Vaccine Endorsed By ACIP For At-Risk Populations

Bavarian Nordic has announced that its single-dose chikungunya vaccine, VIMKUNYA™, has been recommended by the CDC’s Advisory Committee on Immunization Practices (ACIP) for specific at-risk populations. This virus-like particle (VLP) based recombinant vaccine is now officially recommended for individuals aged 12 and older travelling to regions experiencing a chikungunya outbreak. 

Paul Chaplin, President and CEO of Bavarian Nordic, said in a statement, “The ACIP’s recommendation of our chikungunya vaccine for Americans aged 12 and older is a big step forward to expanding access to this vaccine in the United States. Chikungunya is an emerging public health threat worldwide, and today’s decision is another milestone in our mission to protect more people from this virus.”

The ACIP’s recommendation also includes individuals who plan to travel or reside long-term in regions without active outbreaks but with elevated risk for U.S. travellers and laboratory workers who may be exposed to the virus. These targeted groups reflect populations at increased risk of infection, especially as chikungunya is a mosquito-borne virus that can cause severe joint pain and fever. 

According to the CDC, Chikungunya has shown active transmission in over 50 countries in the past five years. The endorsement of VIMKUNYA provides a vital preventive option for travellers and professionals working in at-risk environments.